Lilly to buy gene therapy firm Prevail for $1 billion

16 December 2020

US pharma major Eli Lilly (NYSE: LLY) yesterday revealed that it has signed an agreement to acquire gene therapy company Prevail Therapeutics (Nasdaq: PRVL), with the news sending the latter’s shares roaring up 86% pre-market.

Lilly has agreed to pay $22.50 per Prevail share in cash (or an aggregate of around $880 million) payable at closing plus one non-tradable contingent value right (CVR) worth up to $4.00 per share in cash (or an aggregate of about $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of about $1.040 billion). Lilly’s shares also gained 2%, but that was most likely due to it raising its financial outlook (see below).

The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The transaction is expected to close in the first quarter of 2021

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK